Cadonilimab + 化疗能促进晚期胃癌的存活, Cadonilimab plus chemo boosts survival in advanced stomach cancer, working for all PD-L1 levels with good safety.

第三阶段试验(COMPASSION-15)发现,Cadonilimab与化疗相结合,大大改善了一线先进胃癌或肠道切口癌的总体存活率,经过33.9个月的中位跟踪后,死亡风险降低了39%。 A Phase III trial, COMPASSION-15, found that cadonilimab combined with chemotherapy significantly improved overall survival in first-line advanced gastric or gastroesophageal junction cancer, with a 39% lower risk of death after a median 33.9-month follow-up. 所有PD-L1分组,包括低表达式或负表达式的分组,都看到了效益,治疗显示出一种有利的安全性特征。 Benefits were seen across all PD-L1 subgroups, including those with low or negative expression, and the treatment showed a favorable safety profile. 不论PD-L1状况如何,该药物现在在中国得到批准,并被推荐为第一线选择。 The drug is now approved in China and recommended as a first-line option regardless of PD-L1 status.